25 assets in Breast Adenocarcinoma

Therapeutic assets addressing Breast Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Breast Adenocarcinoma	Second Affiliated Hospital, School of Medicine, Zhejiang University	P3	BB (70)
Adriamycin Breast Adenocarcinoma	Virginia Commonwealth University	P3	BB (68)
Letrozole Breast Adenocarcinoma	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	P4	BB (68)
Carboplatin Breast Adenocarcinoma	Genmab	P3	BB (66)
Pembrolizumab Breast Adenocarcinoma	Genmab	P2	BB (65)
Tamoxifen Breast Adenocarcinoma	National Cancer Institute (NCI)	P3	B (62)
Anastrozole Breast Adenocarcinoma	National Cancer Institute (NCI)	P3	B (60)
Entinostat Breast Adenocarcinoma	National Cancer Institute (NCI)	P3	B (60)
Exemestane Breast Adenocarcinoma	National Cancer Institute (NCI)	P3	B (60)
Goserelin Breast Adenocarcinoma	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	P3	B (60)
Sargramostim Breast Adenocarcinoma	Mayo Clinic	P2	B (60)
Brc-001 Breast Adenocarcinoma	City of Hope Medical Center	P2	CCC (53)
Decitabine Breast Adenocarcinoma	Virginia Commonwealth University	P2	CCC (53)
Durvalumab Breast Adenocarcinoma	Filipa Lynce, MD	P2	CCC (53)
Trastuzumab Deruxtecan Breast Adenocarcinoma	Filipa Lynce, MD	P2	CCC (53)
Immunoglobulin G1 [240-Alanine,241-Alanine], Anti-(Human Folate Receptor ?) (Human Monoclonal Pro1184 ?1-Chain, Complex With Human Monoclonal Pro1184 ?-Chain, Dimer, 214??,214???,226,226?,232,232?,235,235?-Octakis(Thioether) With N6-[39-[Bis(1-Deoxy-D-Glucitol-1-Yl)Amino]-1-Oxo-4,7,10,13,16,19,22,25,28,31,34,37-Dodecaoxanonatriacont-1-Yl]-N2-[6-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-1-Oxohexyl]-L-Lysyl-L-Valyl-N5-(Aminocarbonyl)-N-[4-[[[[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]Carbonyl]Oxy]Methyl]Phenyl]-L-Ornithinamide Breast Adenocarcinoma	Genmab	P1/2	CC (47)
Abemaciclib Breast Adenocarcinoma	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	P1	CC (46)
Ipilimumab Breast Adenocarcinoma	National Cancer Institute (NCI)	P1	CC (46)
Aquocobalamin Breast Adenocarcinoma	General Oncology, Inc.	P1	CC (43)
Camustine Breast Adenocarcinoma	General Oncology, Inc.	P1	CC (43)
Melphalan Breast Adenocarcinoma	General Oncology, Inc.	P1	CC (43)
Nivolumab Breast Adenocarcinoma	Mayo Clinic	P1	CC (43)
Oncolytic Measles Virus Encoding Helicobacter Pylori Neutrophil-Activating Protein Breast Adenocarcinoma	Mayo Clinic	P1	CC (43)